Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siIL-6
- Development stage
- Preclinical
- Lead developer
- Baylor College of Medicine
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
siIL-6 is a small interfering RNA (siRNA) designed to silence the expression of Interleukin-6 (IL-6). In research contexts, particularly in pancreatic cancer studies, it has been used to demonstrate that mesothelin-activated NF-κB induces elevated IL-6 expression, which acts as a growth factor to support tumor cell survival and proliferation. Treatment with siIL-6 has been shown to reduce cell proliferation and cell cycle progression in pancreatic cancer cell lines such as MIA PaCa-2 and Panc1. Furthermore, prolonged treatment with siIL-6 can induce apoptosis and significantly decrease levels of downstream targets like c-myc and bcl-2, highlighting its role in blocking the autocrine/paracrine IL-6/sIL-6R trans-signaling axis.
- Other names
- IL-6 siRNAIL6 siRNAIL 6 siRNAInterleukin-6 siRNAInterleukin6 siRNAInterleukin 6 siRNA
02
Targets
IL-6 (Interleukin 6)
Beyond the preview
Go deeper on siIL-6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siIL-6.